Shanghai, China, October 22, 2025 – Shanghai Henlius Biotech, Inc. (2696.HK) announced that its independently developed innovative anti-PD-1 mAb serplulimab (trade name in Europe: Hetronifly^®) has successfully completed enrolment of all 200 patients in the U.S. bridging clinical study (ASTRIDE) comparing serplulimab plus chemotherapy with atezolizumab plus chemotherapy in previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC). This milestone paves the way for Henlius to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).

Shanghai, China, October 20, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX43, the company's innovative programmed death-ligand 1 (PD-L1) targeting antibody-drug conjugate (ADC), for the treatment of thymic epithelial tumors (TETs).

On 16 October, the 2025 Sustainability Global Leaders Conference was held in Shanghai. Themed “Joining Hands to Address Challenges: Global Action, Innovation, and Sustainable Growth”, the Conference brought together approximately 500 guests from China and abroad, including Nobel Prize laureates, Turing Award laureates, as well as executives from Global 500 companies.

On 12 October 2025, Fosun International Limited (“Fosun International”) and BNP Paribas have signed a strategic cooperation agreement (“Agreement”), committing to collaborate closely in support of Fosun International and its subsidiaries’ (collectively as “Fosun”) future development strategies.

Shanghai, China, October 9, 2025 — Shanghai Henlius Biotech, Inc. (2696.HK) announced that its self-developed innovative anti-PD-1 monoclonal antibody, HANSIZHUANG (serplulimab, Hetronifly^® in Europe), in combination with chemotherapy for the neoadjuvant/adjuvant monotherapy treatment of gastric cancer, has met the primary endpoint of Event-Free Survival (EFS) in an interim analysis of its phase 3 clinical study (ASTRUM-006). This outcome represents a breakthrough, making it the world-first regimen to replace adjuvant chemotherapy with mono-immunotherapy in the perioperative treatment of gastric cancer.

S&P Global recently released the 2025 Corporate Sustainability Assessment (CSA) score results for Fosun International Limited (HKEX stock code: 00656, “Fosun International” or “Fosun”). Fosun International’s S&P Global CSA score has risen to 72 points, significantly outperforming the industry average and maintaining its leading position in the industry.

September 29, 2025, Jeddah, Saudi Arabia – The inauguration ceremony for the Fosun Pharma Middle East Office and Fosunhenlius Middle East United Company was grandly held in Jeddah, Saudi Arabia. This move marks a significant step in Fosun Pharma's localized operations in the Middle East, representing a strategic initiative by the company to continuously expand its global presence through innovation.

SHANGHAI, China & JERSEY CITY, NJ – SEPTEMBER 19, 2025 – Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS^® (denosumab) injection 60 mg/mL and BILPREVDA^® (denosumab) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.

On 9 September 2025, Fosun International Limited (HKEX stock code: 00656, hereinafter referred to as “Fosun International” or the “Company”) was informed that in the 2025 Sustainability Ratings of listed companies released by Hang Seng Indexes Company, Fosun International received an AA- rating for the third consecutive year.